Advanced UTI Treatments Becoming Available

While antibiotics have treated most Urinary Tract Infections (UTIs) over the past, resistance to these medications has been expanding. About 20% of infected people are reportedly resistant to UTI antibiotics.

This is an unfortunate trend, as complicated UTIs may lead to hospitalized florid urosepsis, which can be fatal. 

According to recent news, innovative UTI treatments are accelerating in clinical trials and gaining regulatory approvals to meet the needs of millions of women and men impacted by this common infectious disease.

For example, the U.S. Food and Drug Administration approved UTILITY therapeutics Ltd. Pivya™ (pivmecillinam) in April 2024. This medication is currently available in various countries and is expected to be available in the United States in 2025.

Immunotek S.L. Uromune™ MV140, an inactivated oral spray vaccine that reduces recurrent Urinary Tract Infections, already has limited access in over twenty countries.

Additionally, Recce Pharmaceuticals Limited is developing a new class of Synthetic Anti-Infectives designed to address antibiotic-resistant superbugs and emerging viral pathogens.

Recce reported on May 15, 2024, that it successfully dosed the first male and female participants in the next cohort in its UTI / Urosepsis phase 1/2 clinical trial with RECCE® 327, 4,000mg intravenously, at a fast infusion rate of 20 minutes.

This is the highest dose (4,000mg) tested in participants in this trial with Minimum Inhibitory Concentration activity against bacteria already identified among existing clinical samples with this increase in dose optimization, an essential exercise for regulatory purposes.

RECCE confirmed on May 15, 2024, that the full efficacious potential of R327 via intravenous administration will be made available after this clinical trial is completed.

Earlier in May, China's National Intellectual Property Administration formally Granted a new Patent Family 2 for Recce's anti-infectives "Copolymer and Method for Treatment of Bacterial Infections."

In April 2024, RECCE announced the successful batch completion under Good Manufacturing Practices for RECCE® 327, with the patented manufacturing process now producing 5,000 doses per week.

'As the Company continues to generate promising interim data from its Phase I/II UTI/Urosepsis clinical trial on both safety and efficacy, R327 is showcasing its capability to be administered over multiple fast infusion times, highlighting the potential for a groundbreaking treatment on the first patient presentation in any medical setting,' wrote the Company.

Recce Pharmaceuticals' Head of Manufacturing Arthur Kollaras said in a press release, "We are thrilled to announce the successful batch completion of human pharmaceutical grade R327, representing a crucial step forward in our mission to address the global threat of antimicrobial resistance."

UTIs are common infections caused by bacteria, often from the skin or rectum, entering the urethra and infecting the urinary tract. The infections can affect several parts of the urinary tract, but the most common type is a bladder infection, says the U.S. CDC.